|
KR20190089768A
|
|
Pharmaceutical compositions containing Mirabegron and tamsulosin with improved stability
|
|
KR20190089758A
|
|
Sustained-release preparation containing mirabegron or pharmaceutically acceptable salt thereof
|
|
KR20200050030A
|
|
Composition for external application having improved stability containing elm extracts
|
|
KR20190005132A
|
|
Pharmaceutical composition containing a retinoid with improved bioavailability and stability
|
|
KR20190006897A
|
|
Agents for preventing or treating urinary disease and preparing the same
|
|
KR20180092296A
|
|
Pharmaceutical composition containing omega-3 fatty acid and HMG-CoA reductase inhibitor with improved bioavailability
|
|
KR20190085203A
|
|
Sustained release dosage form including sarpogrelate
|
|
WO2018080284A1
|
|
Pharmaceutical composition for enhancing bioavailability of drug for treatment of acne
|
|
KR20180087114A
|
|
Pharmaceutical composition comprising Mosapride or salt thereof and preparation method for the same
|
|
KR20180048384A
|
|
Pharmaceutical composition with improved bioavailability for acne treatment
|
|
KR101879133B1
|
|
Agents for preventing or treating urinary disease and preparing the same
|
|
KR20180119025A
|
|
Composition for preventing or treating urinary disease and preparing the same
|
|
KR101818882B1
|
|
Pharmaceutical composition for prevention or treatment of infections caused by herpes virus
|
|
KR20180104259A
|
|
Controlled release pharmaceutical composition comprising mirabegron
|
|
WO2017142296A1
|
|
Medical injection device
|
|
KR20170006541A
|
|
Pharmaceutical composition containing cabergoline having enhanced stability
|
|
KR101641372B1
|
|
A pharmaceutical formulation which shows enhanced stability and skin permeability
|
